ERBB2 and neoplasm: Similar results could be seen in patients with advanced breast cancer and discordant HER2 status between the PT and circulating tumor cells (CTCs) isolated from peripheral blood [31], where disease progressed more quickly in patients with an HER2-negative PT and HER2-positive CTCs [32,33].